Newshttp://www.ecco-org.eu/en/Global/rss/AllNews.aspxNewsen{10C6180E-01EE-49F4-B394-2E01C0878FF3}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Incidence-and-m.aspxIncidence and mortality of second sarcomas – A population-based study - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{B568B310-967F-4E3E-A415-AD506656B83A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Incidence-and-m.aspxIncidence and mortality of second sarcomas – A population-based study - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{4D915FE9-12E0-4987-B872-ECBD3A26AC55}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Inhibition-of-p.aspxInhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{EB888EBD-DFBD-466F-8129-C94135BBD46F}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Inhibition-of-p.aspxInhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{EE6567FE-EB78-4E3D-B25C-594D0B7C125E}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Pharmacokinetic.aspxPharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{E9EB3435-B380-4F99-9EEA-FA2B9857C821}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Pharmacokinetic.aspxPharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{A2E9C32F-51CF-427E-9E84-62434577248E}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/The-ruthenium-c.aspxThe ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{5CA1F160-9D80-4BE3-987C-4E2A114FFFA3}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/The-ruthenium-c.aspxThe ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo - Corrected ProofWed, 19 Jun 2013 00:00:00 +0200{4176F147-09E3-42E0-94A3-ADAF561403B1}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/EURECCA-colorec.aspxEURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{034EF575-258C-4431-98F7-17C21C4586B7}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/EURECCA-colorec.aspxEURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{BF2DFC32-38B6-486C-9D32-56A2FF0CD45E}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/High-Ki67-predi.aspxHigh Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{DF5FFAE7-4A51-4B16-BA49-A72DBCD3ACDB}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/High-Ki67-predi.aspxHigh Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{4A6A2332-25FD-41DD-8C85-82FC3D3E75A1}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/How-can-innovat.aspxHow can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{817F44F5-C67F-4500-BA95-F2B4F091D715}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/How-can-innovat.aspxHow can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment? - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{A019C7D7-EEC2-4B62-8A5F-6DA1CEA3D09A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Radioembolisati.aspxRadioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{9772C79A-FDE6-4509-852E-DC65D0B5151A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Radioembolisati.aspxRadioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study - Corrected ProofMon, 17 Jun 2013 00:00:00 +0200{1DC9897E-D029-4CF4-9451-BD772813EC18}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-randomised-ph.aspxA randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation - Corrected ProofWed, 12 Jun 2013 00:00:00 +0200{A2B80D59-BEB8-43F7-BA24-DEB00B41DF20}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/One-year-of-adj.aspxOne year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer - Corrected ProofTue, 11 Jun 2013 00:00:00 +0200{027B0E7C-B96A-4345-983B-C465C7313AEF}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Subsequent-mort.aspxSubsequent mortality experience in five-year survivors of childhood, adolescent and young adult cancer in Scotland: A population based, retrospective cohort study - Corrected ProofTue, 11 Jun 2013 00:00:00 +0200{EEA7BEAE-4989-42DD-B556-970507BDE5CD}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Corrigendum-to.aspxCorrigendum to “miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2” [Eur J Cancer 48(16) (2012) 3104–3111] - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{7E9ADFCD-1982-4061-94DE-9C752C4C8486}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Corrigendum-to.aspxCorrigendum to “miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2” [Eur J Cancer 48(16) (2012) 3104–3111] - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{454B5F58-F3D1-494B-88EB-7DF3F454B6CC}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Radiation_induc.aspxRadiation-induced mitotic cell death and glioblastoma radioresistance: A new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1alpha and survivin in U87 cells - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{3995A060-3C8B-497D-8274-3D57395454FF}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Radiation_induc.aspxRadiation-induced mitotic cell death and glioblastoma radioresistance: A new regulating pathway controlled by integrin-linked kinase, hypoxia-inducible factor 1alpha and survivin in U87 cells - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{40A08200-2D79-421A-B525-C4E0EE13FADD}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Worldwide-trend.aspxWorldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{650FEFA0-1E9B-4C14-83EA-E4E2D3FE9A93}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Worldwide-trend.aspxWorldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors - Corrected ProofMon, 10 Jun 2013 00:00:00 +0200{D2E27BF1-A4C0-4B97-A73F-AA9FE0A57840}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Results-of-doce.aspxResults of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: Results of a randomised Phase 2 study - Corrected ProofFri, 07 Jun 2013 00:00:00 +0200{C9C4DE9B-2F09-4AC7-8266-B9B7DC88ACCB}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Latent-class-an.aspxLatent class analysis identifies three subtypes of aggressive end-of-life care: A population-based study in Taiwan - Corrected ProofThu, 06 Jun 2013 00:00:00 +0200{F0BCA8C7-9E69-4DB0-896B-3DBF1EF377CE}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Latent-class-an.aspxLatent class analysis identifies three subtypes of aggressive end-of-life care: A population-based study in Taiwan - Corrected ProofThu, 06 Jun 2013 00:00:00 +0200{F7A8882B-B9D0-4266-856B-C2B9BAE41AC9}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-cutaneous-lym.aspxA cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{AAE7EF5E-6645-491B-919D-28137DBB766B}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-cutaneous-lym.aspxA cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{3CF83DD3-6596-43DD-AACA-2254048D007C}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-phase-2_-mult.aspxA phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{7F75FC29-F1DC-49FD-8833-D1DB0766E520}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-phase-2_-mult.aspxA phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{96BE886F-BD72-4FDC-86D0-DF1CFFACDEA4}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-randomised-tr.aspxA randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial) - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{277C8022-4919-4D19-BF5B-C4CD3F34B0DA}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/A-randomised-tr.aspxA randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial) - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{113F3DC3-DB7F-42BB-BFB0-4B21F234044B}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Effect-of-visce.aspxEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{1AEFF4F3-636E-4699-A91C-92C333773DCA}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Effect-of-visce.aspxEffect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{7324BDBA-4288-4592-9319-9F3683F248B2}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Impact-of-geria.aspxImpact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{89EED59E-AD38-4AFD-A16B-2D8C458F61A7}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Impact-of-geria.aspxImpact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: Final results of the DOGMES multicentre GINECO trial - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{CB4A2C57-D901-415F-8336-3D36CDF78F2A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Induction-of-pu.aspxInduction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{B30630D2-579F-4FD1-99FF-44D604CF33C3}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Induction-of-pu.aspxInduction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{B908FAD9-0E87-45B8-8098-C2549813C401}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Phase-II-study.aspxPhase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{910D8102-D9C9-424C-9C65-E6C793AB41AB}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Phase-II-study.aspxPhase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{368CCCFD-435F-4613-8A5D-9715C76AAB84}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Response-to-the.aspxResponse to the letter to editor from Richard A. Anderson and co-workers - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{86A42440-8E33-4A5E-9CA5-E69597F8F80E}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Response-to-the.aspxResponse to the letter to editor from Richard A. Anderson and co-workers - Corrected ProofMon, 03 Jun 2013 00:00:00 +0200{217CEE80-1B35-4CAB-B1E9-C9C20691F917}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Basic-cancer-re.aspxBasic cancer research is essential for the success of personalised medicine - Corrected ProofThu, 30 May 2013 00:00:00 +0200{3AE891A8-0D08-46F0-A264-4AB68CD398DE}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Long-non_coding.aspxLong non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer - Corrected ProofThu, 30 May 2013 00:00:00 +0200{4402DD80-DE95-43F6-B340-DF708C6303F7}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Phase-Ib-study.aspxPhase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma - Corrected ProofThu, 30 May 2013 00:00:00 +0200{8D1D3BBE-123F-4A7B-AB08-FB429A230C3D}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/S100A2-is-a-pre.aspxS100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma - Corrected ProofThu, 30 May 2013 00:00:00 +0200{DA076055-8CCD-4940-96A2-886D448E138A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Detection-of-mi.aspxDetection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA - Corrected ProofWed, 29 May 2013 00:00:00 +0200{653EEABF-AFD2-4B9E-ACC0-023BA445B43A}http://www.ecco-org.eu/en/Global/News/rss_ejcancer/Detection-of-mi.aspxDetection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA - Corrected ProofWed, 29 May 2013 00:00:00 +0200